NCT06653218Completed
Efficacy and Safety of Stellate Ganglion Block With Lidocaine Combined Platelet-rich Plasma to Treat Chronic Migraine
Efficacy and Safety of Stellate Ganglion Block With Lidocaine Combined Platelet-rich Plasma to Treat Chronic Migraine: a Protocol of a Multi-center, Prospective, Propensity Score-matched, Cohort Analysis
Source: ClinicalTrials.gov · Last updated 12 Feb 2026
Brief summary (registry, in English)
This is a multicenter, prospective, observational, propensity score matching, cohort, and assessor-blinded study designed to compare the effectiveness and safety of lidocaine combined Platelet-rich plasma (PRP) acting on SGB versus lidocaine alone acting on SGB in patients with CM.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 200 (actual)
- First submitted
- 20 Oct 2024
- Start date
- 20 Oct 2024
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Migraine
- NCT number
- NCT06653218
What you commit to
- Study type: Observational
- Participants enrolled: 200
- From 20 Oct 2024 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received SGB treatment;
- Changes in neck anatomic structure caused by radiotherapy or surgery;
Other illness
- Infection or mass near the puncture site;
- A history of other neurological disorders;
- A history of severe cardiopulmonary, hepatic or renal dysfunction;
- A history of psychological disorders;
- A history of narcotic drug abuse;
- A history of allergies to any research drugs;
Lab values
- Platelet count \<105\*109/L, use of anticoagulants or antiplatelet agent, coagulation disorders or bleeding disorders;
Other
- Combined with other types of headaches;
- Pregnancy or lactation period.
Who the study is looking for
- Age between 18 to 75 years;
- BMI between 15 and 35 kg/m2 ;
- Diagnosed with CM in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria (Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211);
- Visual Analogue Scale (VAS; range, 0-10; 0 = no pain and 10 = worst possible pain; higher scores indicate more severe pain) score≥4;
- Scheduled for lidocaine acting on SGB treatment for CM；
- Signed informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fang Luo Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.